Translating Molecular Pathology Into Cancer Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$2,285,520.00
Summary
Precision oncology, the treatment of cancer patients selected with a particular molecular characteristic (biomarker) matched to a therapy, has transformed the treatment of cancer patients. However, many biomarkers used for clinical care are not reliable and do not perform their role. I will translate new research tests from fundamental discovery, clinical trials and the development of novel diagnostics using innovative high throughput laboratory technologies to enhance patient outcomes.
Optimizing Immunotherapy Treatment For Breast Cancer Patients
Funder
National Health and Medical Research Council
Funding Amount
$1,938,014.00
Summary
The first steps in introducing immunotherapy for breast cancer patients have been taken in 2019. However, there is much work to do optimize immunotherapy for all breast cancer patients. My research, involving both lab and clinical trials, will develop new treatment strategies and identify new biomarkers to distinguish responders and non-responders. This will allow individualised selection of patients for evaluation of different immunotherapy approaches, with the aim of improving their survival.
Defining The Role Of B Lymphocytes In Breast Cancer At Single-cell Resolution
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
B cells, a type of immune cells, are likely protective against breast cancer, albeit through unknown mechanisms. Over the next 5 years I will apply high-resolution profiling and imaging of B cells within breast cancer biopsies to understand their contribution and identify novel clinical targets, leading to better patient outcomes.
The Impact Of Breast Density Notification In Australia
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Breast density is an independent risk factor for breast cancer and it increases the risk of having a cancer missed during screening. Notifying women about their breast density has been endorsed as a way to combat this risk. However, the evidence to support breast density notification and recommendations for supplemental screening in the general population of women is far from clear. This research will provide critical new evidence to ensure that Australian women receive evidence-based care.
Reducing The Burden Of Breast Cancer Through Precision Prevention, Targeted Treatment And Enhanced Survivorship
Funder
National Health and Medical Research Council
Funding Amount
$1,491,192.00
Summary
Breast cancer affects 1 in 8 Australian women. Of all the cancers, breast cancer results in the largest number of years of healthy life lost from death and illness. My research will reduce this unacceptable burden of breast cancer for women and their families. Spanning prevention, through treatment to survivorship, it will facilitate reduced breast cancer incidence, more effective treatments and enhanced understanding of the effects of new treatments on ovarian function and fertility.
Deciphering Mechanisms Underlying Breast Cancer To Improve Patient Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$3,314,215.00
Summary
Breast cancer is a highly heterogeneous disease. Patients are often treated in a ‘one size fits all’ approach, but response to therapy remains disparate. To more effectively personalise therapy, there is a pressing need to define the precise cell types and initiating genetic events that give rise to breast cancer. This application is centred on understanding mechanisms of breast cancer initiation and progression, with the potential of identifying new prognostic markers and therapeutic targets.
Understanding The Genetic Basis Of Breast Cancer: Translation To Primary And Secondary Prevention
Funder
National Health and Medical Research Council
Funding Amount
$2,731,372.00
Summary
We have identified >200 regions of the genome that contain variants that increase breast cancer risk. I will now focus on the main challenges i.e. to a) find the remaining genetic risk factors that will collectively explain all of the genetic risk, b) understand how these work, in particular which genes they influence and c) apply this knowledge to find and develop new drugs. Importantly, such drugs could be used not only to treat breast cancer, but also to prevent it in high-risk women.
Comparative Effectiveness Of Breast Tomosynthesis And Mammography In Real-world Population Screening: Evidence To Underpin And Improve Breast Cancer Screening
Funder
National Health and Medical Research Council
Funding Amount
$1,851,430.00
Summary
This research addresses key evidence gaps in breast cancer screening by investigating tomosynthesis (3D mammography) versus standard 2D mammography screening to establish the effectiveness of tomosynthesis in Australia and internationally, including impact on cancers not detected at screening that progress clinically. Large-scale studies will be done in real world screening services including a prospective comparative study planned collaboratively with BreastScreen to guide screening policy.